Companies (Corporate Social Responsibility Policy) Rules, 2014

Rule No.

Mode of change

Amendment

Effect of amendment

2(1)(e)

Insertion of provision

“Provided that any company engaged in research and development activity of new vaccine, drugs and medical devices in their normal course of business may undertake

research and development activity of new vaccine, drugs and medical devices related to COVID-19 for financial years 2020-21, 2021-22 and 2022-23 subject to the conditions that-

(i) Such research and development activities shall be carried out in collaboration with any of the institutes or organisations mentioned in item (ix) of Schedule VII to the Act.

(ii) Details of such activity shall be disclosed separately in the Annual Report on CSR included in the Board’s Report”.

Research and development activity of new vaccine, drugs and medical devices related to COVID-19 for financial years 2020-21, 2021-22 and 2022-23 are considered under CSR even if the Company is engaged in research and development activity of other vaccine, drugs and medical devices

4(1)

Omission

The words “excluding activities undertaken inpursuance of its normal course of business” shall be omitted.

6(1)

Omission of provision

First proviso shall be omitted